CTA-Sticky-button.png clinicaltrialsyearbook+button
ctsnordics2017-header_v3.jpg

What interactive, new sessions will the 2017 programme include?

We will have an engaging, joint presentation from Novo Nordisk identifying the changes in Annex 13 and how this will impact new labelling strategies. We will have a regulatory expert uncovering the benefits of exploring both regional and national regulations when working with new markets, to ensure all label requirements are met.

After Novo Nordisk’s session we will have the Director of Clinical Trial Management from Ascendis Pharma exploring strategies for simplifying labels whilst reducing cost. This session will also explore the level of text required on labels and how to cope with language barriers.

This will be a great opportunity to ask the speakers questions at the end of their session.

An interactive panel discussion will be held on Day 1 which focusses on clinical supply vendor selection and management and will address the best outsourcing models. We have two senior level speakers from large pharma companies sitting on the panel and they will have a Q&A with the audience to explore their successful vendor selection processes. Attendees will be encouraged to ask questions and discuss ideas for possible solutions.

Both Day 1 and 2 will conclude with roundtable sessions. These will allow attendees to choose topics that are most interesting to them and discuss challenges in more detail with their peers. The kind of topics that will be addressed include, Brexit: how will this affect future trial documentation; Discussing how the ‘last mile’ can make or break your study; Exploring the latest technologies available for real time monitoring.

Join us in Copenhagen in June 2017 for another exciting, collaborative CTS event!

Countdown to Clinical Trial Supply Nordics 2017






300x250-Subscribe-for-updates-banner+version+2.jpg